Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study.

MLA

You, Jianhua, et al. “Real-World Clinical Outcomes of Tixagevimab/Cilgavimab in the Omicron Outbreak in China: Baseline Characteristics and Interim Analysis of the CLEAR Study.” Virology Journal, vol. 21, no. 1, Oct. 2024, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12985-024-02509-5.

APA

You, J., Wu, H., Tian, J., Wen, J., Shi, W., Wang, Z., Du, Y., Xu, H., Wei, H., Li, X., Kang, W., Zhou, M., Gu, Z., & Qu, J. (2024). Real-world clinical outcomes of tixagevimab/cilgavimab in the Omicron outbreak in China: baseline characteristics and interim analysis of the CLEAR study. Virology Journal, 21(1), 1–9. https://doi.org/10.1186/s12985-024-02509-5

Chicago

You, Jianhua, Haidi Wu, Jiaxin Tian, Jianru Wen, Wenbo Shi, Zhi Wang, Yanjun Du, et al. 2024. “Real-World Clinical Outcomes of Tixagevimab/Cilgavimab in the Omicron Outbreak in China: Baseline Characteristics and Interim Analysis of the CLEAR Study.” Virology Journal 21 (1): 1–9. doi:10.1186/s12985-024-02509-5.